<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1110211121
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Zostivr
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FAMCICLOVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1100.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Famciclovir Tablets is an antiviral medicine. It stops the infecting virus from reproducing. Since the virus reproduces very early in the infection, you will benefit most from treatment if you take Famciclovir Tablets as soon as the first symptoms appear.</p><p>Famciclovir Tablets is used to treat two types of viral infections in adults:</p><p>-&nbsp;&nbsp;&nbsp; Shingles (herpes zoster), which is a viral infection caused by a virus called varicella zoster (the same virus that causes chickenpox). Famciclovir Tablets stops the virus from spreading in the body so that healing can occur faster.</p><p>-&nbsp;&nbsp;&nbsp; Famciclovir Tablets is also used for the treatment of shingles in the area around the eye or of the eye itself (ophthalmic zoster).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Genital herpes. Genital herpes is a viral infection caused by herpes simplex virus type 1 or 2. It is normally spread by sexual contact. It causes blisters and burning or itching around the genitals, which</p><p>&nbsp;</p><p>may be painful. Famciclovir Tablets is used to treat genital herpes infections in adults. People who have frequent episodes of genital herpes can also take Famciclovir Tablets to help to prevent the attacks.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Famciclovir Tablets</strong></p><p>If you are allergic to famciclovir, to any of the other ingredients of this medicine (listed in section 6), or to penciclovir (the active metabolite of famciclovir and an ingredient of some other medicines).</p><p><strong>Ask your doctor for advice</strong>, if you think you may be allergic.</p><p>&nbsp;</p><p>Talk to your doctor before taking Famciclovir Tablets. Warnings and precautions</p><p>Talk to your doctor before taking Famciclovir Tablets</p><p>-&nbsp; If you have kidney problems (or have had them before). Your doctor may decide to give you a lower dose of Famciclovir Tablets.</p><p>-&nbsp; If you have problems with your body&rsquo;s immune system.</p><p>-&nbsp; If you have liver problems.</p><p>If any of these applies to you, tell your doctor before you take Famciclovir Tablets. <u>Children and adolescents (below the age of 18 years)</u></p><p>Famciclovir Tablets is not recommended for use in children and adolescents.</p><p>&nbsp;</p><p>Prevent passing genital herpes to others</p><p>If you are taking Famciclovir Tablets to treat or to suppress genital herpes, or you have had genital herpes in the past, you should still practise safe sex, including the use of condoms. This is important to prevent you passing the infection on to others. You should not have sex if you have genital sores or blisters.</p><p>&nbsp;</p><p>Other medicines and Famciclovir Tablets</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>It is especially important that you tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp; Raloxifen (used to prevent and treat osteoporosis).</p><p>&middot;&nbsp; Probenecid (used to treat high blood levels of uric acid associated with gout and to increase blood levels of penicillin-type antibiotics), or any other medicine that can affect your kidneys.</p><p>&nbsp;</p><p>Famciclovir Tablets with food and drink</p><p>You can take Famciclovir Tablets with or without food.</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Famciclovir Tablets is not to be used during pregnancy unless clearly necessary. Your doctor will discuss with you the potential risks of taking Famciclovir Tablets during pregnancy.</p><p>Famciclovir Tablets is not to be used during breast-feeding unless clearly necessary. Your doctor will discuss with you the possible risks of taking Famciclovir Tablets during breast-feeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Famciclovir Tablets can cause dizziness, drowsiness or confusion. <strong>Do not drive or use machines </strong>if you have any of these symptoms while taking Famciclovir Tablets.</p><p>&nbsp;</p><p>Famciclovir Tablets contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, e.g. lactose, contact your doctor before taking this medicine (Famciclovir Tablets 125 mg and 250 mg tablets only).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The daily dose and length of treatment will depend on the type of viral infection you have &ndash; see below. Your doctor will prescribe the correct dose for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; For the best results start the medicine as soon as possible after the first signs and symptoms appear.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not have sexual contact with anyone if you have symptoms of genital herpes &ndash; even if you have started treatment with Famciclovir Tablets. This is because you could pass the herpes infection to your partner.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have had kidney problems, your doctor may decide to give you a lower dose of Famciclovir Tablets.</p><p>&nbsp;</p><p>Dose for shingles</p><p>If you have a <u>normal immune system</u>, the recommended dose is 500 mg three times a day, for seven days. If you have a <u>reduced immune system</u>, the recommended dose is 500 mg three times a day, for ten days.</p><p>&nbsp;</p><p>Dose for genital herpes</p><p>The dose depends on the state of your immune system, and the stage of your infection. If you have a <u>normal immune system</u>, the doses are as follows:</p><p>For the first outbreak, the recommended dose is 250 mg three times a day, for five days. To treat further outbreaks, the recommended dose is 125 mg twice a day, for five days. To prevent future outbreaks, the recommended dose is 250 mg twice a day.</p><p>&nbsp;</p><p>Your doctor will tell you how long you need to continue taking your tablets.</p><p>&nbsp;</p><p>If you have a <u>reduced immune system</u>, the doses are as follows:</p><p>To treat the current outbreak, the recommended dose is 500 mg twice a day, for seven days. To prevent future outbreaks, the dose is 500 mg twice a day.</p><p>&nbsp;</p><p>Your doctor will tell you how long you need to continue taking your tablets.</p><p>&nbsp;</p><p>If you take more Famciclovir Tablets than you should</p><p>If you have taken more tablets than you have been told to take, or if someone else accidentally takes your medicine, go to your doctor or hospital for advice immediately. Show them your pack of tablets.</p><p>Taking too much Famciclovir Tablets may affect the kidneys. In people who already have kidney problems it may, rarely, lead to kidney failure if their dose is not correctly lowered.</p><p>&nbsp;</p><p>If you forget to take Famciclovir Tablets</p><p>If you forget to take a dose of Famciclovir Tablets, you should take it as soon as you remember. Then take your next dose as scheduled. However, do not take two doses within a time interval of less than 1 hour, in that case you should skip the missed dose. Furthermore, do not take a double dose to make up for forgotten dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><u>Serious side effects of Famciclovir Tablets are:</u></p><p>Most of these side effects are rare or uncommon (they affect between 1 to 100 in every 10,000 patients)</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Severe blistering </strong>of the skin or mucous membranes of the lips, eyes, mouth, nasal passages or genitals (these could be signs of a serious allergic skin reaction).</p><p>&nbsp;</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Unexplained bruising</strong>, reddish or purplish patches on the skin or <strong>nosebleeds </strong>(these could be signs of a decrease in the number of blood platelets).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Swelling </strong>below the surface of the skin (e.g. facial swelling, swelling around eye, eyelid swelling, throat swelling).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Yellowing </strong>of the skin and/or eyes (signs of jaundice).</p><p>The frequency of the following side effects is not known (cannot be estimated from the available data):</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Purple skin patches, itching, burning (signs of inflamed blood vessels).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Seizures or fits.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Difficulty breathing or swallowing. Rash, itching, hives, wheezing or coughing, light headedness, dizziness, changes in levels of consciousness. Hypotension, with or without generalised itching, skin reddening, facial/throat swelling, blue discoloration of the lips, tongue or skin (signs of severe allergic reaction).</p><p>&nbsp;</p><p><strong>Contact a doctor or go to the emergency department at your nearest hospital straight away </strong>if you get any of these effects.</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(these side effects affect more than 1 in 10 people)</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Headache</p><p>&nbsp;</p><p><strong>Common side effects </strong>(these side effects affect up to 1 in 10 people)</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Feeling sick (nausea)</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Vomiting</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Abdominal pain</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Diarrhoea</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Dizziness</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Rash</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Itching</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Liver function test giving abnormal results</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(these side effects affect up to 1 in 100 people)</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Confusion</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Drowsiness (usually in the elderly)</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Itchy rash (urticaria)</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(these side effects affect up to 1 in 1,000 people)</p><p>&nbsp;</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Hallucinations (seeing or hearing things that are not really there)</p><p><!--[if !supportLists]-->-&nbsp; <!--[endif]-->Palpitations (signs of abnormal heart beat)</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>Saudi Arabia:</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:116.2pt;margin-top:14.35pt;width:359.9pt;height:117.3pt;
  z-index:-251658240;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".42pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.2pt;margin-right:60.15pt;
     margin-bottom:0in;margin-left:4.85pt;margin-bottom:.0001pt;line-height:
     153%'><span style='mso-font-width:105%'>The<span style='letter-spacing:
     -1.1pt'> </span>National<span style='letter-spacing:-1.1pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-1.15pt'> </span>and<span style='letter-spacing:
     -1.05pt'> </span>Drug<span style='letter-spacing:-1.1pt'> </span>Safety<span
     style='letter-spacing:-1.0pt'> </span>Centre<span style='letter-spacing:
     -1.15pt'> </span>(NPC) o Fax:<span style='letter-spacing:-.4pt'> </span>+966-11-205-7662</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
     0in;margin-left:4.85pt;margin-bottom:.0001pt;line-height:12.65pt;
     mso-line-height-rule:exactly'><span style='mso-font-width:105%'>o Call NPC
     at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0in;margin-bottom:
     0in;margin-left:13.3pt;margin-bottom:.0001pt;text-indent:-8.5pt;
     mso-list:l0 level1 lfo1;tab-stops:13.35pt'><![if !supportLists]><span
     style='mso-font-width:102%'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='mso-font-width:105%'>Toll free phone:<span
     style='letter-spacing:-.4pt'> </span>8002490000</span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.75pt;margin-right:0in;margin-bottom:
     0in;margin-left:13.3pt;margin-bottom:.0001pt;text-indent:-8.5pt;
     mso-list:l0 level1 lfo1;tab-stops:13.35pt'><![if !supportLists]><span
     style='mso-font-width:102%'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='mso-font-width:105%'>E-mail:<span
     style='letter-spacing:-.15pt'> </span></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue;mso-font-width:
     105%;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0in;margin-bottom:
     0in;margin-left:13.3pt;margin-bottom:.0001pt;text-indent:-8.5pt;
     mso-list:l0 level1 lfo1;tab-stops:13.35pt'><![if !supportLists]><span
     style='mso-font-width:102%'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span><span style='mso-font-width:105%'>Website:<span
     style='letter-spacing:-.2pt'> </span></span><a
     href="http://www.sfda.gov.sa/npc"><span style='color:blue;mso-font-width:
     105%;text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--><!--[if !vml]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="484" height="160" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o	Toll free phone: 8002490000
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[endif]--><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp; Store below 30&deg;C.</p><p>&bull;&nbsp; Store in the original package in order to protect from moisture.</p><p>&bull;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&bull;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Famciclovir Tablets contains Famciclovir Tablets 250</strong></p><p>Each film coated tablet contains Famciclovir 250mg.</p><p><strong>The other ingredients are: </strong>Lactose monohydrate, Sodium starch Glycolate, Hydroxy propyl cellulose, Magnesium stearate.</p><p>&nbsp;</p><p><strong>Coating Composition: </strong>Titanium Dioxide, HPMC 2910/Hypromellose 3 cP, HPMC 2910/Hypromellose 6 cP, Macrogol/PEG 400, Polysorbate 80.</p><p>Famciclovir Tablets 500</p><p>Each film coated tablet contains Famciclovir 500mg.</p><p><strong>The other ingredients are: </strong>Lactose monohydrate, Sodium starch Glycolate, Hydroxy propyl cellulose, Magnesium stearate.</p><p><strong>Coating Composition: </strong>Titanium Dioxide, HPMC 2910/Hypromellose 3 cP, HPMC 2910/Hypromellose 6 cP, Macrogol/PEG 400, Polysorbate 80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Famciclovir Tablets 250:

White to off white round biconvex, film coated tablets debossed with ‘I’ on one side and ‘49’ on the other side.

Famciclovir Tablets 500:

White to off white oval, film coated, biconvex tablets, debossed with ‘I’ on one side and ‘48’ on the other side.

How supplied:

Famciclovir Tablets 250mg and 500mg are supplied in Blister pack.

Famciclovir Tablets 250mg and 500mg – 3 X 10’s Alu- White, Opaque PVC/PVdC Blister Pack Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 221</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تنتمي زوستيفر أقراص إلى مجموعة من الأدوية تسمى مضادات الفيروسات. &nbsp;حيث تعمل على وقف الفيروس المسبب للعدوى من التكاثر. ونظرًا لأن الفيروس يتكاثر في مراحل مبكرة من الإصابة، فلكي تستفيد أكثر من العلاج ينبغي تتناول زوستيفر أقراص بمجرد ظهور الأعراض الأولية.</p><p dir="RTL">تستخدم زوستيفر أقراص لعلاج نوعين من الالتهابات الفيروسية لدى البالغين:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القوباء المنطقية (الهربس النطاقي)، وهي عدوى فيروسية يسببها فيروس يسمى فارسيلا زوستر (فيروس جدري الماء النطاقي). حيث تعمل زوستيفر أقراص على وقف انتشار الفيروس في الجسم بحيث يمكن أن يحدث الشفاء بشكل أسرع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تستخدم زوستيفر أقراص أيضًا في علاج القوباء المنطقية في المنطقة المحيطة بالعين أو في العين نفسها (النطاق العيني).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهربس التناسلي. هربس الأعضاء التناسلية هو عدوى فيروسية تسببها فيروس الهربس البسيط من النوع 1 أو2. وينتشر عادة عن طريق الاتصال الجنسي. ويسبب البثور وحرقان أو حكة حول الأعضاء التناسلية، والتي قد تكون مؤلمة. تستخدم زوستيفر أقراص لعلاج عدوى الهربس التناسلي لدى البالغين. كما أنه يستخدم للمساعدة في منع هذه العدوى من العودة مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال زوستيفر أقراص:</strong></p><p dir="RTL">إذا كنت تعاني من حساسية تجاه فامسيكلوفير أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6)، أو إلى مادة بنسيكلوفير (ناتج أيض المادة الفعالة فامسيكلوفير ومكون لبعض الأدوية الأخرى).</p><p dir="RTL"><strong>اسأل طبيبك للحصول على المشورة، إذا كنت تعتقد أنك قد تكون تعاني من الحساسية.</strong></p><p dir="RTL"><strong>تحدث إلى طبيبك قبل تناول زوستيفر أقراص.</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول زوستيفر أقراص إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في الكلى (في الوقت الحالي أومن قبل) قد يقرر طبيبك إعطائك جرعة أقل من زوستيفر أقراص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان الجهاز المناعي لديك ضعيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تكن متأكدًا ما إذا كان أي مما سبق ينطبق عليك، فتحدث إلى طبيبك أو الصيدلي قبل تناول زوستيفر أقراص.</p><p dir="RTL"><u>الأطفال والمراهقون (أقل من 18 عامًا)</u></p><p dir="RTL">لا يُنصح باستخدام زوستيفر أقراص في حالة الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>منع </u></strong><strong><u>انتقال عدوى</u></strong><strong><u> القوباء التناسلية إلى الآخرين</u></strong></p><p dir="RTL">إذا كنت تتناول زوستيفر أقراص لعلاج أو منع الإصابة بعدوى الهربس التناسلي، أوكنت قد عانيت من القوباء التناسلية مسبقا، فلا يزال عليك ممارسة الجنس بشكل آمن، وذلك باستخدام الواقي الذكري. هذا مهم لمنع نقل العدوى إلى الآخرين. يجب ألا تمارس الجنس إذا كان لديك تقرحات أو بثور.</p><p dir="RTL"><strong>تناول أدوية أخرى مع زوستيفر أقراص </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أي أدوية أخرى مؤخرًا. بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">من المهم أن تخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا مما الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رالوكسيفين (يستخدم لمنع وعلاج مرض هشاشة العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبنسيد (يستخدم لعلاج ارتفاع مستويات حمض اليوريك في الدم المرتبطة بالنقرس وزيادة مستويات الدم من المضادات الحيوية من نوع البنسلين)، أو أي دواء آخر يمكن أن يؤثر على الكليتين.</p><p dir="RTL"><strong>تناول زوستيفر أقراص مع الطعام والشراب</strong></p><p dir="RTL">يمكنك تناول زوستيفر أقراص مع أو بدون طعام.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو ترضعين طفلك، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاطلب نصيحة الطبيب قبل تناول هذا الدواء. لا يتم استخدام زوستيفر أقراص خلال فترة الحمل إلا إذا كان ذلك ضروريًا بشكل واضح. سيناقش طبيبك معك المخاطر المحتملة لتناول زوستيفر أقراص أثناء فترة الحمل.</p><p dir="RTL">لا يتم استخدام زوستيفر أقراص أثناء الرضاعة الطبيعية إلا إذا كان ذلك ضروريًا بشكل واضح. سيناقش طبيبك معك المخاطر المحتملة لتناول زوستيفر أقراص أثناء الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب زوستيفر أقراص دوخة أو خمول أو ارتباك. لا تقود السيارة أو تستخدم الآلات إذا كان لديك أي من هذه الأعراض أثناء تناول زوستيفر أقراص.</p><p dir="RTL"><strong>محتوي زوستيفر أقراص من اللاكتوز</strong></p><p dir="RTL">إذا أخبر طبيبك أن لديك مشكلة تجاه تناول بعض السكريات، على سبيل المثال اللاكتوز، اتصل بطبيبك قبل تناول هذا الدواء (زوستيفر أقراص 125 ملغم و250 ملغم فقط).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب أو الصيدلي. تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتمد الجرعة اليومية وطول فترة العلاج على نوع العدوى الفيروسية التي تعاني منها - انظر أدناه. سيصف لك الطبيب الجرعة الصحيحة المناسبة لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للحصول على أفضل النتائج، ابدأ بتناول الدواء في أسرع وقت ممكن بعد ظهور العلامات والأعراض الأولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم الاتصال الجنسي مع أي شخص إذا كان لديك أعراض الهربس التناسلي - حتى لوكنت قد بدأت العلاج بتناول زوستيفر أقراص. هذا لأنه يمكنك نقل عدوى الهربس إلى شريك حياتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلى أوقد تعاني منها، فقد يقرر طبيبك إعطائك جرعة أقل من زوستيفر أقراص.</p><p dir="RTL"><strong>جرعة </strong><strong>علاج القوباء</strong><strong> المنطقية</strong></p><p dir="RTL">إذا كان لديك <u>جهاز مناعي طبيعي</u>، فإن الجرعة الموصي بها هي 500 ملغم ثلاث مرات في اليوم، لمدة سبعة أيام. إذا كان لديك <u>نظام مناعي منخفض</u>، فإن الجرعة الموصي بها هي 500 ملغم ثلاث مرات في اليوم، لمدة عشرة أيام.</p><p dir="RTL"><strong>جرعة</strong><strong> علاج</strong><strong> للهربس التناسلي</strong></p><p dir="RTL">تعتمد الجرعة على حالة الجهاز المناعي لديك، ومرحلة العدوى.</p><p dir="RTL">إذا كان لديك جهاز مناعي طبيعي، تكون الجرعات كما يلي:</p><p dir="RTL">بالنسبة لعلاج حالة التفشي الأولية، تكون الجرعة الموصي بها 250 ملغم ثلاث مرات في اليوم، لمدة خمسة أيام.</p><p dir="RTL">بالنسبة لعلاج حالة تفشي المرض مرة أخرى، تبلغ الجرعة الموصي بها 125 ملغم مرتين في اليوم، لمدة خمسة أيام.</p><p dir="RTL">لمنع تفشي المرض في المستقبل، فإن الجرعة الموصي بها هي 250 ملغم مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك كم من الوقت تحتاج إلى الاستمرار في تناول زوستيفر أقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من انخفاض في نظام المناعة، فإن الجرعات ستصبح كما يلي:</p><p dir="RTL">لعلاج حالة تفشي المرض الحالي، الجرعة الموصي بها هي 500 ملغم مرتين في اليوم، لمدة سبعة أيام.</p><p dir="RTL">لمنع تفشي المرض مستقبلا، تكون الجرعة 500 ملغم مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك كم من الوقت تحتاج إلى الاستمرار في تناول أقراصك.</p><p dir="RTL"><strong>الجرعة الزائدة من زوستيفر أقراص</strong></p><p dir="RTL">إذا تناولت أقراصًا أكثر مما طلب منك تناوله، أو إذا تناول شخص آخر الدواء عن طريق الخطأ، فانتقل إلى طبيبك أو المستشفى للحصول على المشورة على الفور. ويجب أن تأخذ عبوة الأقراص معك.</p><p dir="RTL">تناول جرعة زائدة من زوستيفر أقراص قد يؤثر على الكلى. في الأشخاص الذين يعانون بالفعل من مشاكل في الكلى، نادراً ما يؤدي ذلك إلى الفشل الكلوي إذا لم يتم تخفيض الجرعة بشكل صحيح.</p><p dir="RTL"><strong>نسيان تناول أقراص من زوستيفر أقراص</strong></p><p dir="RTL">إذا نسيت تناول جرعة من زوستيفر أقراص، فيجب أن تتناولها حالما تتذكرها. ثم تناول الجرعة التالية كما هو مقرر. ومع ذلك، لا تتناول جرعتين خلال فترة زمنية أقل من ساعة واحدة، في هذه الحالة يجب عليك تخطي الجرعة الفائتة. علاوة على ذلك، لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL"><u>الآثار الجانبية الخطيرة لأقراص زوستيفر هي:</u></p><p dir="RTL">معظم الآثار الجانبية التالية نادرة أو غير شائعة (حيث تؤثر على ما بين 1 إلى 100 من كل 10,000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور تقرحات شديدة في الجلد أو الأغشية المخاطية للشفاه أو العينين أو الفم أو الممرات الأنفية أو الأعضاء التناسلية (قد تكون هذه أعراض حدوث تفاعل حساسية خطيرة في الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء أو أرجوانية على الجلد بشكل غير مفسرة أو نزيف من الأنف (يمكن أن تكون هذه علامات انخفاض في عدد الصفائح الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم تحت سطح الجلد (مثل تورم الوجه، تورم حول العين، تورم الجفن، تورم الحلق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد و/ أو العينين (أعراض اليرقان).</p><p dir="RTL">معدل الآثار الجانبية التالية غير معروف (لا يمكن تقدير معدلاتها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع الجلد الأرجوانية اللون، والحكة، وحرقان (أعراض التهابات بالأوعية الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات أو تشنجات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أو البلع. الطفح الجلدي، والحكة، وخلايا الشرى، والأزيز أو السعال، والدوخة الخفيفة، والتغيرات في مستويات الوعي. انخفاض ضغط الدم، مع أو بدون حكة معممة، احمرار الجلد، تورم في الوجه / الحلق، تلون الشفاه للأزرق أو اللسان أو الجلد (علامات الحساسية الشديدة).</p><p dir="RTL">اتصل بالطبيب أو اذهب إلى قسم الطوارئ في أقرب مستشفى على الفور إذا واجهت أي من هذه الآثار.</p><p dir="RTL">آثار جانبية شائعة جدًا (تؤثر هذه الآثار الجانبية على أكثر من شخص من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">الآثار الجانبية الشائعة (هذه الآثار الجانبية تؤثر على ما يصل إلى 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (غثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع بالبطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلهف، متشوق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار وظائف الكبد مع ظهور نتائج غير طبيعية</p><p dir="RTL">آثار جانبية غير شائعة (تؤثر هذه الآثار الجانبية على ما يصل إلى 1 من كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس (عادة في كبار السن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة الطفح الجلدي (الشرى)</p><p dir="RTL">آثار جانبية نادرة (هذه الآثار الجانبية تؤثر على ما يصل إلى 1 من كل 1000 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلوسة (رؤية أو سماع أشياء ليست موجودة بالفعل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان (ضربات القلب غير الطبيعية)</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيفية تخزين </strong><strong>زوستيفر أقراص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ عند درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم زوستيفر أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أوعن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحتويه زوستيفر أقراص 250 ملغم</strong></p><p dir="RTL">المادة الفعالة هي فامسيكلوفير.</p><p dir="RTL">زوستيفر أقراص 250</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 250 ملغم من فامسيكلوفير.</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: اللاكتوز أحادي الهيدرات، نشا الصوديوم جليكولات، هيدروكسي بروبيل السليلوز، ستيرات الماغنيسيوم..</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: ثاني أكسيد التيتانيوم، هيبروميلوز3 cP / HPMC 2910، بولي إيثيلين جليكول / ماكروجول، بولي سوربات 80.</p><p dir="RTL"><strong>ما تحتويه زوستيفر أقراص 500 ملغم</strong></p><p dir="RTL">المادة الفعالة هي فامسيكلوفير.</p><p dir="RTL">زوستيفر أقراص 500</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 500 ملغم من فامسيكلوفير.</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: اللاكتوز أحادي الهيدرات، نشا الصوديوم جليكولات، هيدروكسي بروبيل السليلوز، ستيرات الماغنيسيوم..</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: ثاني أكسيد التيتانيوم، هيبروميلوز3 cP / HPMC 2910، بولي إيثيلين جليكول / ماكروجول، بولي سوربات 80.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>زوستيفر أقراص </strong><strong>250</strong><strong> ملغم</strong></p><p dir="RTL">أقراص دائرية الشكل محدبة الوجهين ذات لون أبيض إلى الأبيض القاتم، والأقراص مغلفة بطبقة رقيقة ومدموغة بحرف &quot;I&quot; من جانب و&quot;49&quot; على الجانب الآخر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>زوستيفر أقراص 500 ملغم</strong></p><p dir="RTL">أقراص بيضاوية الشكل محدبة الوجهين ذات لون أبيض إلى الأبيض القاتم، والأقراص مغلفة بطبقة رقيقة ومدموغة بحرف &quot;I&quot; من جانب و&quot;48&quot; على الجانب الآخر.</p><p dir="RTL"><strong>توافر زوستيفر أقراص:</strong></p><p dir="RTL">يتوافر زوستيفر أقراص 250 ملغم و500 ملغم في عبوات حاوية.</p><p dir="RTL">تحتوي عبوة زوستيفر أقراص 500 ملغم و250 ملغم على 30 قرص عبارة عن ثلاثة شرائط مصنوعة من Alu. PVC/PVDC بكل منها 10 أقراص</p><p dir="RTL">قد لا تتوافر كافة العبوات في السوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: + 966 114772215</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Famciclovir Tablets 500mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Famciclovir Tablets 500  
Each film coated tablet contains Famciclovir 500mg. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Famciclovir Tablets 500:  
White to off white oval, film coated, biconvex tablets, debossed with ‘I’ on one side and ‘48’ on the other side. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Varicella zoster virus (VZV) infections &ndash; herpes zoster</p><p>Famciclovir Tablets is indicated for</p><p>-&nbsp; the treatment of herpes zoster and ophthalmic zoster in immunocompetent adults (see section 4.4)</p><p>-&nbsp; the treatment of herpes zoster in immunocompromised adults (see section 4.4)</p><p>Herpes simplex virus (HSV) infections &ndash; genital herpes</p><p>Famciclovir Tablets is indicated for</p><p>-&nbsp; the treatment of first and recurrent episodes of genital herpes in immunocompetent adults</p><p>-&nbsp; the treatment of recurrent episodes of genital herpes in immunocompromised adults</p><p>-&nbsp; the suppression of recurrent genital herpes in immunocompetent and immunocompromised adults</p><p>Clinical studies have not been conducted in HSV-infected patients immunocompromised for other causes than HIV infection (see section 5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Herpes zoster and ophthalmic zoster in immunocompetent adults</u> 500 mg three times daily for seven days.</p><p>Treatment should be initiated as soon as possible after a diagnosis of herpes zoster or ophthalmic zoster.</p><p><u>Herpes zoster in immunocompromised adults</u> 500 mg three times daily for ten days.</p><p>Treatment should be initiated as soon as possible after a diagnosis of herpes zoster.</p><p>Genital herpes in immunocompetent adults</p><p>First episode of genital herpes: 250 mg three times daily for five days. Initiation of treatment is recommended as soon as possible after a diagnosis of first episode of genital herpes. Episodic treatment of recurrent genital herpes: 125 mg twice daily for five days. Initiation of treatment is recommended as soon as possible after onset of prodromal symptoms (e.g. tingling, itching, burning, pain) or lesions.</p><p>Recurrent genital herpes in immunocompromised adults</p><p>Episodic treatment of recurrent genital herpes: 500 mg twice daily for seven days. Initiation of treatment is recommended as soon as possible after onset of prodromal symptoms (e.g. tingling, itching, burning, pain) or lesions.&nbsp;</p><p>Suppression of recurrent genital herpes in immunocompetent adults</p><p>250 mg twice daily. Suppressive therapy should be discontinued after a maximum of 12 months of continuous antiviral therapy to reassess recurrence frequency and severity. The minimum period of reassessment should include two recurrences. Patients who continue to have significant disease may restart suppressive therapy.</p><p><u>Suppression of recurrent genital herpes in immunocompromised adults</u>&nbsp; 500 mg twice daily.</p><p>Patients with renal impairment</p><p>Because reduced clearance of penciclovir is related to reduced renal function, as measured by creatinine clearance, special attention should be given to doses in patients with impaired renal function. Dose recommendations for adult patients with renal impairment are provided in Table</p><p>1.</p><p>Table 1 Dose recommendations for adult patients with renal impairment</p><table border="0" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication and nominal dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clearance </strong></p><p><strong>[ml/min] </strong></p></td><td style="vertical-align:top"><p><strong>Adjusted dose regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Herpes&nbsp;&nbsp;&nbsp; zoster&nbsp; in immunocompetent adults </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>500 mg three times daily for 7 days<strong> </strong></p></td><td style="vertical-align:top"><p>&ge; 60</p></td><td style="vertical-align:top"><p>500 mg three times daily for</p><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>40 to 59</p></td><td style="vertical-align:top"><p>500 mg twice daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20 to 39</p></td><td style="vertical-align:top"><p>500 mg once daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>250 mg once daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemodialysis patients</p></td><td style="vertical-align:top"><p>250 &nbsp;&nbsp;&nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each dialysis during 7 days</p></td></tr><tr><td style="vertical-align:top"><p><strong>Herpes zoster&nbsp; in immunocompromised adults </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>500 mg three times daily for 10 days</p></td><td style="vertical-align:top"><p>&ge; 60</p></td><td style="vertical-align:top"><p>500 mg three times daily for</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>40 to 59</p></td><td style="vertical-align:top"><p>500 mg twice daily for 10 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20 to 39</p></td><td style="vertical-align:top"><p>500 mg twice daily for 10 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>250 mg once daily for 10 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemodialysis patients</p></td><td style="vertical-align:top"><p>250 &nbsp;&nbsp;&nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each dialysis during 10 days</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; <strong>Genital &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in </strong></p><p><strong>immunocompetent adults &ndash; </strong></p><p><strong>first episode of genital herpes </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>250 mg three times daily for 5 days</p></td><td style="vertical-align:top"><p>&ge; 40</p></td><td colspan="2" style="vertical-align:top"><p>250 mg three times daily for</p><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20 to 39</p></td><td colspan="2" style="vertical-align:top"><p>250 mg twice daily for 5 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td colspan="2" style="vertical-align:top"><p>250 mg once daily for 5 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemodialysis patients</p></td><td colspan="2" style="vertical-align:top"><p>250 &nbsp;&nbsp;&nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each dialysis during 5 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; <strong>Genital &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in </strong></p><p><strong>immunocompetent adults &ndash; episodic treatment of </strong></p><p><strong>recurrent genital herpes </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>125 mg twice daily for 5 days</p></td><td style="vertical-align:top"><p>&ge; 20</p></td><td colspan="2" style="vertical-align:top"><p>125 mg twice daily for 5 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td colspan="2" style="vertical-align:top"><p>125 mg once daily for 5 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemodialysis patients</p></td><td colspan="2" style="vertical-align:top"><p>125 &nbsp;&nbsp;&nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each dialysis during 5 days</p></td></tr><tr><td style="vertical-align:top"><p><strong>Genital herpes in immunocompromised adults </strong></p><p><strong>&ndash; </strong></p><p>&nbsp;&nbsp; <strong>episodic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of </strong></p><p><strong>recurrent genital herpes </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>500 mg twice daily for 7 days</p></td><td style="vertical-align:top"><p>&ge; 40</p></td><td colspan="2" style="vertical-align:top"><p>500 mg twice daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20 to 39</p></td><td colspan="2" style="vertical-align:top"><p>500 mg once daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td colspan="2" style="vertical-align:top"><p>250 mg once daily for 7 days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemodialysis patients</p></td><td colspan="2" style="vertical-align:top"><p>250 &nbsp;&nbsp;&nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each dialysis during 7&nbsp; days</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; <strong>Suppression &nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp; recurrent </strong></p><p>&nbsp;&nbsp; <strong>genital &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>immunocompetent adults </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>250 mg twice daily</p></td><td style="vertical-align:top"><p>&ge; 40</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20 to 39</p></td><td style="vertical-align:top"><p>125 mg twice daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>125 mg once daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemodialysis patients</p></td><td style="vertical-align:top"><p>125 &nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following dialysis</p></td><td style="vertical-align:top"><p>each</p></td></tr><tr><td style="vertical-align:top"><p><strong>Suppression &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp; recurrent </strong></p><p><strong>genital &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in </strong></p><p><strong>immunocompromised adults </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>&ge; 40</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20 to 39</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>250 mg once daily</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemodialysis patients</p></td><td style="vertical-align:top"><p>250 &nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; following dialysis</p></td><td style="vertical-align:top"><p>each</p></td></tr></tbody></table><p>Patients with renal impairment on haemodialysis</p><p>Since 4 h haemodialysis resulted in up to 75% reduction in plasma penciclovir concentrations, Famciclovir should be administered immediately following dialysis. The recommended dose regimens for haemodialysis patients are included in Table 1.</p><p>Patients with hepatic impairment</p><p>No dose adjustment is required in patients with mild or moderate hepatic impairment. No data are available for patients with severe hepatic impairment (see sections 4.4 and 5.2).</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_19076" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:96.75pt;height:11.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="129" height="15" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>Dose modification is not required unless renal function is impaired.</p><p>Paediatric population</p><p>The safety and efficacy of Famciclovir in children and adolescents aged less than 18 years have not been established. Currently available data are described in sections 5.1 and 5.2.</p><p>Method of administration</p><p>Famciclovir Tablets can be taken without regard to meals (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Hypersensitivity to penciclovir. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use in patients with renal impairment</u></p><p>In patients with impaired renal function dose adjustment is necessary (see sections 4.2 and 4.9).</p><p>Use in patients with hepatic impairment</p><p>Famciclovir has not been studied in patients with severe hepatic impairment. Conversion of famciclovir to its active metabolite penciclovir may be impaired in these patients resulting in lower penciclovir plasma concentrations, and thus a decrease of efficacy of famciclovir may occur.</p><p>Use for zoster treatment</p><p>Clinical response should be closely monitored, particularly in immunocompromised patients. Consideration should be given to intravenous antiviral therapy when response to oral therapy is considered insufficient.</p><p>Patients with complicated herpes zoster, i.e. those with visceral involvement, disseminated zoster, motor neuropathies, encephalitis and cerebrovascular complications should be treated with intravenous antiviral therapy.</p><p>Moreover, immunocompromised patients with ophthalmic zoster or those with a high risk for disease dissemination and visceral organ involvement should be treated with intravenous antiviral therapy.</p><p>Transmission of genital herpes</p><p>Patients should be advised to avoid intercourse when symptoms are present even if treatment with an antiviral has been initiated. During suppressive treatment with antiviral agents, the frequency of viral shedding is significantly reduced. However, transmission is still possible. Therefore, in addition to therapy with Famciclovir, it is recommended that patients use safer sex practices.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of other medicinal products on famciclovir</p><p>No clinically significant interactions have been identified.</p><p>Concurrent use of probenecid may result in increased plasma concentrations of penciclovir, the active metabolite of famciclovir, by competing for elimination.</p><p>Therefore, patients receiving famciclovir at a dose of 500 mg three times daily co-administered with probenecid, should be monitored for toxicity. If patients experience severe dizziness, somnolence, confusion or other central nervous system disturbances, a dose reduction of famciclovir to 250 mg three times daily may be considered.</p><p>Famciclovir needs aldehyde oxidase to be converted into penciclovir, its active metabolite. Raloxifen has been shown to be a potent inhibitor of this enzyme <em>in vitro</em>. Co-administration of raloxifene could affect the formation of penciclovir and thus the efficacy of famciclovir. When raloxifen is co-administered with famciclovir the clinical efficacy of the antiviral therapy should be monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child-bearing potential</u></p><p>There are no data supporting any special recommendations in women of child-bearing potential. Patients with genital herpes should be advised to avoid intercourse when symptoms are present even if treatment has been initiated. It is recommended that patients use safer sex practice (see section 4.4).</p><p><u>Pregnancy</u></p><p>There is a limited amount of data (less than 300 pregnancy outcomes) from the use of famciclovir in pregnant women. Based on these limited amounts of information, the cumulative analysis of both prospective and retrospective pregnancy cases did not provide evidence indicating that the product causes any specific foetal defect or congenital anomaly. Animal studies have not shown any embryotoxic or teratogenic effects with famciclovir or penciclovir (the active metabolite of <u>famciclovir). Famciclovir should only be used during pregnancy when the potential benefits of treatment outweigh the potential risks.</u></p><p><u>Breast-feeding</u></p><p>It is unknown whether famciclovir is excreted in human breast milk. Animal studies have shown excretion of penciclovir in breast milk. If the woman&#39;s condition mandates treatment with famciclovir, discontinuation of breastfeeding may be considered.</p><p><u>Fertility</u></p><p>Clinical data do not indicate an impact of famciclovir on male fertility following long-term treatment at an oral dose of 250 mg twice daily (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, patients who experience dizziness, somnolence, confusion or other central nervous system disturbances while taking Famciclovir Tablets should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Headache and nausea have been reported in clinical studies. These were generally mild or moderate in nature and occurred at a similar incidence in patients receiving placebo treatment. All other adverse reactions were added during post marketing.</p><p>The pooled global placebo or active controlled clinical trials (n=2326 for Famciclovir Tablets arm) were retrospectively reviewed to obtain a frequency category for all adverse reactions mentioned below. The following table specifies the estimated frequency of adverse reactions based on all the spontaneous reports and literature cases that have been reported for Famciclovir Tablets since its introduction to the market.</p><p>Adverse reactions (Table 2) are ranked under headings of frequency, using the following convention: very common (&ge;1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from available data).</p><p>Table 2 Adverse reactions from clinical trials and post-marketing spontaneous reports</p><table border="0" cellspacing="0" cellpadding="0" style="width:601px"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Thrombocytopenia.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Confusional state (predominantly in the</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:601px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>elderly).</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hallucinations.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Somnolence (predominantly in the elderly).</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Seizure*.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Palpitations.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nausea, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, diarrhoea.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Abnormal liver function tests.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Cholestatic jaundice.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Anaphylactic &nbsp; shock*, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaphylactic reaction*.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:<strong> </strong></p></td><td style="vertical-align:top"><p>Rash, pruritus.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:<strong> </strong></p></td><td style="vertical-align:top"><p>Angioedema (e.g. face oedema, eyelid oedema, periorbital oedema, pharyngeal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>oedema), urticaria.</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Serious skin reactions* (e.g. erythema multiforme, Stevens-Johnson Syndrome,</p><p>Toxic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epidermal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Necrolysis),</p><p>Hypersensitivity vasculitis*.</p></td></tr></tbody></table><p>*Adverse drug reactions reported from post-marketing experience with Famciclovir Tablets via spontaneous case reports and literature cases which have not been reported in clinical trials. Because these adverse drug reactions have been reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. Frequency is therefore listed as &ldquo;not known&rdquo;.</p><p>Overall, adverse reactions reported from clinical studies with immunocompromised patients were similar to those reported in the immunocompetent population. Nausea, vomiting and abnormal liver function tests were reported more frequently, especially at higher doses.</p><p><u><strong>Reporting of suspected adverse reactions&nbsp;</strong></u></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em>Saudi Arabia: </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>Other GCC States: </strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose experience with famciclovir is limited. In the event of an overdose supportive and symptomatic therapy should be given as appropriate. Acute renal failure has been reported rarely in patients with underlying renal disease where the famciclovir dose has not been appropriately reduced for the level of renal function. Penciclovir is dialysable; plasma concentrations are reduced by approximately 75% following 4 h haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Nucleosides and nucleotides excluding reverse transcriptase inhibitors, ATC code: J05AB09</p><p>Mechanism of action&nbsp;</p><p>Famciclovir is the oral prodrug of penciclovir. Famciclovir is rapidly converted in vivo into penciclovir, which has in vitro activity against herpes simplex viruses (HSV types 1 and 2), varicella zoster virus (VZV), Epstein-Barr virus and cytomegalovirus.</p><p>The antiviral effect of orally administered famciclovir has been demonstrated in several animal models: this effect is due to in vivo conversion to penciclovir. In virus-infected cells the viral thymidine kinase (TK) phosphorylates penciclovir to a monophosphate form that, in turn, is converted to penciclovir triphosphate by cellular kinases. This triphosphate inhibits viral DNA chain elongation by competitive inhibition with deoxyguanosine triphosphate for incorporation into the growing viral DNA, thus halting virus replication of viral DNA. Penciclovir triphosphate has an intracellular half-life of 10 hours in HSV-1-, 20 hours in HSV-2- and 7 hours in VZVinfected cells grown in culture. In uninfected cells treated with penciclovir, concentrations of penciclovir-triphosphate are only barely detectable. Hence the probability of toxicity to mammalian host cells is low and uninfected cells are unlikely to be affected by therapeutic concentrations of penciclovir.</p><p>Resistance&nbsp;</p><p>Like aciclovir, penciclovir resistance is associated with mutations principally in the thymidine kinase (TK) gene resulting in deficiency or altered substrate specificity of this enzyme, and to a much lesser extent in the DNA polymerase gene. Most aciclovir-resistant HSV and VZV clinical isolates are also resistant to penciclovir, but cross-resistance is not universal.</p><p>Results from 11 worldwide clinical studies involving penciclovir (topical or intravenous formulations) or famciclovir in immunocompetent or immunocompromised patients, including studies of up to 12 months treatment with famciclovir, have shown a small overall frequency of penciclovir resistant isolates: 0.2% (2/913) in immunocompetent patients and 2.1% (6/288) in immunocompromised patients. The resistant isolates were mostly found at the start of treatment or in a placebo group, with resistance occurring on or after treatment with famciclovir or penciclovir only in two immunocompromised patients.</p><p>Clinical efficacy&nbsp;</p><p>In placebo-controlled and active-controlled studies both in immunocompetent and immunocompromised patients with uncomplicated herpes zoster, famciclovir was effective in the resolution of lesions. In an active-controlled clinical study, famciclovir was shown to be effective in the treatment of ophthalmic zoster in immunocompetent patients.</p><p>Efficacy of famciclovir in immunocompetent patients with first episode of genital herpes was shown in three active-controlled studies. Two placebo-controlled studies in immunocompetent patients and one-active controlled study in HIV-infected patients with recurrent genital herpes showed that famciclovir was effective.</p><p>Two placebo-controlled 12-month studies in immunocompetent patients with recurrent genital herpes showed that famciclovir-treated patients had a significant reduction of recurrences as compared to placebo-treated patients. Placebo-controlled and uncontrolled studies of up to 16 weeks duration showed that famciclovir was effective in the suppression of recurrent genital herpes in HIV-infected patients; the placebo-controlled study showed that famciclovir significantly decreased the proportion of days of both symptomatic and asymptomatic HSV shedding.</p><p>Paediatric population&nbsp;</p><p>Famciclovir experimental oral granules were evaluated in 169 paediatric patients 1 month to &le;12 years of age. One hundred of these patients were 1 to &le;12 years of age and were treated with famciclovir oral granules (doses ranged from 150 mg to 500 mg) either twice (47 patients with herpes simplex virus infections) or three times (53 patients with chickenpox) daily for 7 days. The remaining 69 patients (18 patients 1 to &le;12 months, 51 patients 1 to &le;12 years) participated in single-dose pharmacokinetic and safety studies using famciclovir oral granules (doses ranged from 25 mg to 500 mg). Famciclovir weight-based doses were selected to provide penciclovir systemic exposures similar to the penciclovir systemic exposures observed in adults after administration of 500 mg famciclovir. None of these studies comprised a control group; therefore a conclusion on the efficacy of the investigated regimens is not possible. The safety profile was similar to that seen in adults. However, systemic drug exposure in infants &lt; 6 months of age was low, thus precluding any assessment of famciclovir&#39;s safety in this age group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General characteristics</u>&nbsp;</p><p>Absorption&nbsp;</p><p>Famciclovir is the oral prodrug of the antivirally active compound penciclovir. Following oral administration, famciclovir is rapidly and extensively absorbed and converted to penciclovir. Bioavailability of penciclovir after oral administration of famciclovir was 77%. Mean peak plasma concentration of penciclovir, following a 125 mg, 250 mg, 500 mg and 750 mg oral dose of famciclovir, was 0.8 microgram/ml, 1.6 micrograms/ml, 3.3 micrograms/ml and 5.1 micrograms/ml, respectively, and occurred at a median time of 45 minutes post-dose.</p><p>Plasma concentration-time curves of penciclovir are similar following single and repeat (t.i.d. and b.i.d.) dosing, indicating that there is no accumulation of penciclovir on repeated dosing with famciclovir.</p><p>The extent of systemic availability (AUC) of penciclovir from oral famciclovir is unaffected by food.</p><p><u>Distribution</u>&nbsp;</p><p>Penciclovir and its 6-deoxy precursor are poorly (&lt; 20%) bound to plasma proteins.</p><p>Metabolism and elimination&nbsp;</p><p>Famciclovir is eliminated principally as penciclovir and its 6-deoxy precursor, which are excreted in urine. No unchanged famciclovir has been detected in urine. Tubular secretion contributes to the renal elimination of penciclovir.</p><p>The terminal plasma half-life of penciclovir after both single and repeat dosing with famciclovir was approximately 2 hours.</p><p>Evidence from preclinical studies has shown no potential for induction of cytochrome P450 enzymes and inhibition of CYP3A4.</p><p>Characteristics in special populations&nbsp;</p><p>Patients with herpes zoster infection&nbsp;</p><p>Uncomplicated herpes zoster infection does not significantly alter the pharmacokinetics of penciclovir measured after the oral administration of famciclovir. The terminal plasma half-life of penciclovir in patients with herpes zoster was 2.8 h and 2.7 h, respectively, after single and repeated dosing of famciclovir.</p><p>Subjects with renal impairment&nbsp;</p><p>The apparent plasma clearance, renal clearance, and plasma elimination rate constant of penciclovir decreased linearly with reductions in renal function, both after single and repeated dosing. Dose adjustment is necessary in patients with renal impairment (see section 4.2).</p><p>Subjects with hepatic impairment&nbsp;</p><p>Mild and moderate hepatic impairment had no effect on the extent of systemic availability of penciclovir following oral administration of famciclovir. No dose adjustment is recommended for patients with mild and moderate hepatic impairment (see sections 4.2 and 4.4). The pharmacokinetics of penciclovir have not been evaluated in patients with severe hepatic impairment. Conversion of famciclovir to the active metabolite penciclovir may be impaired in these patients resulting in lower penciclovir plasma concentrations, and thus possibly a decrease of efficacy of famciclovir.</p><p>Paediatric population&nbsp;</p><p>Repeated oral dosing of famciclovir (250 or 500 mg three times daily) to paediatric patients (611 years) infected with hepatitis B did not have a notable effect on the pharmacokinetics of penciclovir compared to single dose data. There was no accumulation of penciclovir. In children (1-12 years) with herpes simplex virus infection or chickenpox given single oral doses of famciclovir (see section 5.1), the apparent clearance of penciclovir increased with body weight in a nonlinear manner. The plasma elimination half-life of penciclovir tended to decrease with decreasing age, from an average of 1.6 hours in the patients aged 6-12 years to 1.2 hours in patients aged 1-&lt;2 years.</p><p>Elderly (&ge; 65 years)&nbsp;</p><p>Based on cross-study comparisons, the mean penciclovir AUC was about 30% higher and penciclovir renal clearance about 20% lower after oral administration of famciclovir in older volunteers (65-79 years) compared to younger volunteers. Partly this difference may be due to differences in renal function between the two age groups. No dose adjustment based on age is recommended unless renal function is impaired (see section 4.2).</p><p>Gender&nbsp;</p><p>Small differences in renal clearance of penciclovir between females and males have been reported and were attributed to gender differences in renal function. No dose adjustment based on gender is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General toxicity</u>&nbsp;</p><p>Studies on safety pharmacology and repeated dose toxicity reveal no special hazard for humans.</p><p>Genotoxicity&nbsp;</p><p>Famciclovir was not found to be genotoxic in a comprehensive battery of <em>in vivo</em> and <em>in vitro</em> tests designed to detect gene mutation, chromosomal damage and repairable damage to DNA. Penciclovir, in common with other substances of this class, has been shown to cause mutations/chromosomal aberrations in human lymphocytes and in the L5178Y mouse lymphoma assay at concentrations at least 25-fold to 100-fold, respectively higher than the maximum concentration reached in human plasma after a single oral famciclovir dose of 1500 mg. Penciclovir was negative in the bacterial Ames test and there was no evidence of increased DNA repair <em>in vitro</em>.&nbsp;</p><p>Penciclovir caused an increased incidence of micronuclei in mouse bone marrow in vivo when administered intravenously at doses highly toxic to bone marrow (&ge; 500 mg/kg corresponding to &ge; 810 times the maximum human dose based on body surface area conversion).</p><p>Carcinogenicity&nbsp;</p><p>At high doses in female rats, there was an increased incidence of mammary adenocarcinoma, a tumour commonly observed in the strain of rats used in the carcinogenicity study. There was no effect on the incidence of neoplasia in male rats treated at doses up to 240 mg/kg/day (corresponding to a 38.4 mg/kg human equivalent dose or 1.3-fold of the highest recommended total daily dose of 1500 mg famciclovir or a patient of 50 kg body weight) or in mice of either sex at doses up to 600 mg/kg/day (corresponding to a 48 mg/kg human equivalent dose or 1.6fold of the highest recommended total daily dose).</p><p>Reproductive toxicity&nbsp;</p><p>Impaired fertility (including histopathological changes in the testis, altered sperm morphology, reduced sperm concentration and motility, and reduced fertility) was observed in male rats after 10 weeks of dosing at 500 mg/kg/day (corresponding to a 80 mg/kg human equivalent dose or 2.7-fold of the highest recommended total daily dose). Furthermore, testicular toxicity was noted in the general toxicity studies. This finding was reversible and has also been observed with other substances of this class. Animal studies did not indicate any negative effect on female fertility at doses up to 1000 mg/kg/day (corresponding to a 160 mg/kg human equivalent dose or 5.3-fold of the highest recommended total daily dose).</p><p>Embryofetal development studies showed no evidence of adverse effects at oral doses of famciclovir and intravenous doses of penciclovir corresponding to 0.7- to 5.3- fold of the highest recommended total daily dose of famciclovir.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Famciclovir Tablets 500 &nbsp;</p><p>Each film coated tablet contains Famciclovir 500mg.</p><p><strong>The other ingredients are:</strong> Lactose monohydrate, Sodium starch Glycolate, Hydroxy propyl cellulose, Magnesium stearate.</p><p><strong>Coating Composition:</strong> Titanium Dioxide, HPMC 2910/Hypromellose 3 cP, HPMC</p><p>2910/Hypromellose 6 cP,&nbsp; Macrogol/PEG 400, Polysorbate 80.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Famciclovir Tablets&nbsp; 500mg are supplied in blister pack.</p><p>Famciclovir Tablets 500mg&nbsp; &ndash; 3 X 10&rsquo;s Alu- White, Opaque PVC/PVdC Blister Pack Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab Ltd. 
Aljameah Street, Malaz quarter,  
Riyadh 11441, Saudi Arabia 
Tel: +966 11 477 2215
Manufacture: 
Hetero Lab Limited Unit V, Jadcherla, India. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>